CA
NZ
UK
AU
IND
US
…
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Pasithea Therapeutics Corp is a clinical-stage biopharmaceutical company developing therapeutics for neuropsychiatric disorders, including programs based on psychedelic-inspired compounds. Long-term growth may be driven by clinical progress, regulatory approvals, and broader acceptance of novel mental-health treatments. Investors may find the company attractive because successful trials could address large unmet needs and enable licensing or commercialization opportunities.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | -13.94M | -2.17M | - |
| Net income | -13.06M | -2.17M | - |
| Selling general administrative | 12.52M | 4.51M | - |
| Gross profit | 0.37M | -0.00M | - |
| Reconciled depreciation | 0.03M | 0.00M | - |
| Ebit | -14.82M | -4.51M | -0.06M |
| Ebitda | -14.74M | -4.51M | - |
| Depreciation and amortization | 0.08M | 0.00M | - |
| Operating income | -14.82M | -4.51M | - |
| Other operating expenses | 15.30M | 4.52M | - |
| Interest expense | 0.00M | 0.00M | 0.00M |
| Tax provision | 0.00M | 0.00M | - |
| Net interest income | -0.00M | -0.00M | - |
| Income tax expense | -0.88M | 0.00M | - |
| Total revenue | 0.49M | 0.02M | - |
| Total operating expenses | 15.19M | 4.51M | - |
| Cost of revenue | 0.11M | 0.02M | - |
| Total other income expense net | 0.88M | 2.33M | - |
| Net income from continuing ops | -13.94M | -2.17M | - |
| Net income applicable to common shares | - | -2.17M | -0.06M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 26.12M | 45.18M | 53.32M | 0.25M |
| Intangible assets | 7.94M | 8.59M | - | - |
| Other current assets | 0.36M | 0.63M | 0.33M | 0.00M |
| Total liab | 2.72M | 2.68M | 1.90M | 0.01M |
| Total stockholder equity | 23.40M | 42.50M | 51.42M | 0.24M |
| Other current liab | 2.55M | 1.61M | 0.45M | 0.01M |
| Common stock | 0.00M | 0.02M | 0.02M | 0.01M |
| Capital stock | 0.00M | 0.02M | 0.02M | 0.01M |
| Retained earnings | -35.32M | -19.36M | -2.21M | -0.04M |
| Other liab | - | - | 1.45M | - |
| Good will | 1.26M | 1.26M | - | - |
| Other assets | 0.00M | - | - | - |
| Cash | 16.33M | 33.15M | 52.97M | 0.24M |
| Total current liabilities | 2.63M | 1.88M | 0.45M | 0.01M |
| Current deferred revenue | -2.55M | - | - | - |
| Net debt | -16.25M | -32.22M | -52.97M | -0.24M |
| Short term debt | 0.08M | 0.26M | - | - |
| Short long term debt total | 0.08M | 0.93M | - | - |
| Other stockholder equity | 58.72M | 61.84M | 53.63M | 0.27M |
| Property plant equipment | - | - | 0.02M | - |
| Total current assets | 16.69M | 34.08M | 53.30M | 0.25M |
| Net tangible assets | - | - | 51.42M | 0.24M |
| Net receivables | 0.04M | 0.30M | - | - |
| Inventory | -0.04M | - | - | - |
| Accounts payable | 2.55M | - | 0.45M | 0.01M |
| Accumulated other comprehensive income | -0.00M | -0.00M | -0.01M | - |
| Non currrent assets other | -9195.02M | - | 0.00M | - |
| Non current assets total | 9.42M | 11.10M | 0.02M | 0.00M |
| Capital lease obligations | 0.08M | 0.93M | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | -2.06M | -0.02M | - |
| Change to liabilities | - | 0.44M | 0.01M |
| Total cashflows from investing activities | - | -0.02M | -0.02M |
| Total cash from financing activities | -3.21M | 55.93M | 0.42M |
| Change to operating activities | - | -0.33M | -0.01M |
| Net income | -13.94M | -2.17M | -0.06M |
| Change in cash | -19.82M | 52.72M | 0.37M |
| Begin period cash flow | 52.97M | 0.24M | - |
| End period cash flow | 33.15M | 52.97M | 0.24M |
| Total cash from operating activities | -14.56M | -3.17M | -0.06M |
| Issuance of capital stock | 0.00M | 50.24M | - |
| Depreciation | 0.03M | 0.00M | 0.00M |
| Sale purchase of stock | -3.21M | - | - |
| Other cashflows from financing activities | -2.06M | 5.69M | -1.31M |
| Change to netincome | - | -1.11M | -1.11M |
| Capital expenditures | 2.14M | 0.02M | 0.02M |
| Change in working capital | -0.14M | 0.11M | - |
| Stock based compensation | 0.55M | 0.47M | - |
| Other non cash items | -1.07M | 0.75M | - |
| Free cash flow | -16.70M | -3.20M | - |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| KTTA Pasithea Therapeutics Corp |
0.06 11.31% |
0.58 | - | - | 42.15 | 0.33 | 277.44 | 0.55 |
| NVO Novo Nordisk A/S |
0.01 0.02% |
40.31 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
4.59 0.85% |
547.09 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
1.45 0.16% |
904.35 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
| Name | Title | Year Born |
|---|---|---|
| Dr. Lawrence Steinman BA, M.D. | Exec. Chairman & Co-Founder | 1948 |
| Dr. Tiago Reis Marques | CEO & Director | 1977 |
| Mr. Daniel H. Schneiderman | Chief Financial Officer | 1978 |
| Dr. Yassine Bendiabdallah Ph.D. | COO & Head of UK Clinics | 1985 |
| Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder, MD & Executive Chairman | 1948 |
| Dr. Tiago Reis Marques M.D., Ph.D. | CEO & Director | 1978 |
| Dr. Graeme Currie Ph.D. | Chief Development Officer | 1967 |
| Dr. Yassine Bendiabdallah Ph.D. | COO & Head of UK Clinics | 1984 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...